학술논문
Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab.
Document Type
Article
Author
Source
Japanese Journal of Clinical Oncology; May2022, Vol. 52 Issue 5, p479-485, 7p
Subject
Language
ISSN
03682811